JP6162144B2 - ４，４−二置換−１，４−ジヒドロピリミジン、及びｂ型肝炎の処置のための医薬としてのその使用 - Google Patents

４，４−二置換−１，４−ジヒドロピリミジン、及びｂ型肝炎の処置のための医薬としてのその使用 Download PDF

Info

Publication number
JP6162144B2
JP6162144B2 JP2014550706A JP2014550706A JP6162144B2 JP 6162144 B2 JP6162144 B2 JP 6162144B2 JP 2014550706 A JP2014550706 A JP 2014550706A JP 2014550706 A JP2014550706 A JP 2014550706A JP 6162144 B2 JP6162144 B2 JP 6162144B2
Authority
JP
Japan
Prior art keywords
mmol
compound
minutes
concentrated
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014550706A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508402A (ja
Inventor
ヴァンディック，コーエン
イボン ポール ハチェ，ギアウィン
イボン ポール ハチェ，ギアウィン
ロムボウツ，ギート
ヴァーシュレン，ウィム，ガストン
ラボイソン，ピエール，ジャン−マリー，バーナード
Original Assignee
ヤンセン・サイエンシズ・アイルランド・ユーシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン・サイエンシズ・アイルランド・ユーシー filed Critical ヤンセン・サイエンシズ・アイルランド・ユーシー
Publication of JP2015508402A publication Critical patent/JP2015508402A/ja
Application granted granted Critical
Publication of JP6162144B2 publication Critical patent/JP6162144B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014550706A 2012-01-06 2013-01-04 ４，４−二置換−１，４−ジヒドロピリミジン、及びｂ型肝炎の処置のための医薬としてのその使用 Expired - Fee Related JP6162144B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12150384.1 2012-01-06
EP12150384 2012-01-06
EP12167065.7 2012-05-08
EP12167065 2012-05-08
PCT/EP2013/050095 WO2013102655A1 (fr) 2012-01-06 2013-01-04 1,4-dihydropyrimidines 4,4-disubstituées et leur utilisation en tant que médicaments pour le traitement de l'hépatite b

Publications (2)

Publication Number Publication Date
JP2015508402A JP2015508402A (ja) 2015-03-19
JP6162144B2 true JP6162144B2 (ja) 2017-07-19

Family

ID=47520114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014550706A Expired - Fee Related JP6162144B2 (ja) 2012-01-06 2013-01-04 ４，４−二置換−１，４−ジヒドロピリミジン、及びｂ型肝炎の処置のための医薬としてのその使用

Country Status (12)

Country Link
US (1) US9233933B2 (fr)
EP (1) EP2800742B1 (fr)
JP (1) JP6162144B2 (fr)
KR (1) KR102056665B1 (fr)
CN (1) CN104302626B (fr)
AR (1) AR089671A1 (fr)
AU (1) AU2013207205B2 (fr)
CA (1) CA2858647C (fr)
EA (1) EA026977B1 (fr)
ES (1) ES2581489T3 (fr)
UY (1) UY34566A (fr)
WO (1) WO2013102655A1 (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2649410T3 (es) 2011-12-21 2018-01-11 Novira Therapeutics Inc. Agentes antivirales para la hepatitis B
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2013144129A1 (fr) * 2012-03-31 2013-10-03 F. Hoffmann-La Roche Ag Nouveaux 4-méthyl-dihydropyrimidines pour le traitement et la prophylaxie du virus de l'hépatite b
EP2888241B1 (fr) 2012-08-24 2017-07-12 Sunshine Lake Pharma Co., Ltd. Dérivés de la 3,6-dihydropyrimidine substitués 2,4,5,6- en tant qu'inhibiteurs de la polymerase du virus de la hépatite B (VHB) pour le traitement p.e. de la hépatite chronique
AP2015008248A0 (en) 2012-08-28 2015-02-28 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
JP6113285B2 (ja) 2012-09-10 2017-04-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療及び予防用の６−アミノ酸ヘテロアリールジヒドロピリミジン
ES2628953T3 (es) 2013-02-28 2017-08-04 Janssen Sciences Ireland Uc Sulfamoilarilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis B
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
SI3024819T1 (en) 2013-07-25 2018-06-29 Janssen Sciences Ireland Uc Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B
DK3060547T3 (en) 2013-10-23 2018-01-15 Janssen Sciences Ireland Uc CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B
RU2678990C1 (ru) 2013-11-19 2019-02-05 Саншайн Лейк Фарма Ко., Лтд. Соединения дигидропиримидина и их применение в фармацевтических препаратах
CA2927373C (fr) 2013-11-27 2021-07-13 Sunshine Lake Pharma Co., Ltd. Procedes de preparation de derives de dihydropyrimidine, et intermediaires de ceux-ci
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
ES2792848T3 (es) 2014-02-05 2020-11-12 Novira Therapeutics Inc Politerapia para el tratamiento de infecciones por VHB
JP6495929B2 (ja) 2014-02-06 2019-04-03 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイルピロールアミド誘導体およびｂ型肝炎の治療のための医薬としてのその使用
EP3974426A1 (fr) 2014-03-13 2022-03-30 Indiana University Research and Technology Corporation Modulateurs allostériques des protéines du noyau de l'hépatite b
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
US9771358B2 (en) 2014-03-28 2017-09-26 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
CN105859708B (zh) 2015-02-07 2020-01-21 广东东阳光药业有限公司 二氢嘧啶衍生物的盐及其在药物中的应用
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2016183266A1 (fr) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Agents antiviraux de l'hépatite b
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10179131B2 (en) 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
TWI730985B (zh) 2015-09-15 2021-06-21 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
CN108430971A (zh) 2015-09-29 2018-08-21 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
US10280175B2 (en) 2016-02-02 2019-05-07 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
KR102398439B1 (ko) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
EP3442524A2 (fr) 2016-04-15 2019-02-20 Novira Therapeutics Inc. Associations et méthodes comprenant un inhibiteur d'ensemble capside
BR112018075465A2 (pt) 2016-06-10 2019-03-19 Enanta Pharmaceuticals, Inc. agentes antivirais de hepatite b
WO2018053157A1 (fr) 2016-09-15 2018-03-22 Assembly Biosciences, Inc. Modulateurs des protéines du noyau de l'hépatite b
CA3055194A1 (fr) 2017-03-02 2018-09-07 Assembly Biosciences, Inc. Composes de sulfamide cyclique et leurs procedes d'utilisation
EP3645516A4 (fr) 2017-06-27 2021-07-07 Janssen Pharmaceutica NV Dérivés hétéroaryldihydropyrimidine et méthodes de traitement d'infections par le virus de l'hépatite b
CA3073986A1 (fr) 2017-08-28 2019-03-07 Enanta Pharmaceuticals, Inc. Agents antiviraux contre l'hepatite b
GEP20227373B (en) 2017-11-02 2022-04-25 Aicuris Gmbh & Co Kg Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
MA50520A (fr) 2017-11-02 2020-09-09 Aicuris Gmbh & Co Kg Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb)
US10723733B2 (en) 2017-12-06 2020-07-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019113173A1 (fr) * 2017-12-06 2019-06-13 Enanta Pharmaceuticals, Inc. Agents antiviraux contre l'hépatite b
WO2019143902A2 (fr) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Hétérocycles substitués utiles en tant qu'agents antiviraux
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019214610A1 (fr) * 2018-05-08 2019-11-14 Janssen Sciences Ireland Unlimited Company Dérivés de dihydropyrimidine et leurs utilisations dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
TW202024093A (zh) 2018-09-21 2020-07-01 美商安塔製藥公司 作為抗病毒劑之官能化雜環
MA53983A (fr) 2018-10-22 2021-12-15 Assembly Biosciences Inc Composés d'hétéroaryle carboxamide à 5 chaînons pour le traitement du vhb
US20210395751A1 (en) 2018-10-31 2021-12-23 The University Of Sydney Compositions and methods for treating viral infections
AR116946A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
AR116947A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
UY38435A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
UY38434A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
CN113039187A (zh) 2018-11-02 2021-06-25 艾库里斯有限及两合公司 抗乙型肝炎病毒HBV的脲6,7-二氢-4H-噻唑并[5,4-c]吡啶活性剂
UY38437A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
KR20210093951A (ko) 2018-11-21 2021-07-28 이난타 파마슈티칼스, 인코포레이티드 항바이러스제로서의 작용화된 헤테로사이클
WO2020125729A1 (fr) 2018-12-20 2020-06-25 Janssen Pharmaceutica Nv Dérivés d'hétéroaryldihydropyrimidine et procédés de traitement d'infections par le virus de l'hépatite b
BR112021015618A2 (pt) 2019-02-22 2021-10-05 Janssen Sciences Ireland Unlimited Company Derivados de amida úteis no tratamento da infecção pelo hbv ou doenças induzidas pelo hbv
EP3962912A1 (fr) 2019-04-30 2022-03-09 AiCuris GmbH & Co. KG Nouvelles urées de phényle et de pyridyle actives contre le virus de l'hépatite b (vhb)
WO2020221826A1 (fr) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Nouveaux indole-2-carboxamides actifs contre le virus de l'hépatite b (vhb)
EP3962909B1 (fr) 2019-04-30 2023-10-04 AiCuris GmbH & Co. KG Nouvelles pipérazines d'oxalyle actives contre le virus de l'hépatite b (vhb)
US20220227789A1 (en) 2019-04-30 2022-07-21 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
AU2020269897A1 (en) 2019-05-06 2021-10-14 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
EP3975996A1 (fr) 2019-05-24 2022-04-06 Assembly Biosciences, Inc. Compositions pharmaceutiques pour le traitement du vhb
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
WO2020255016A1 (fr) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combinaison de vaccins contre le virus de l'hépatite b (vhb) et de dérivés de dihydropyrimidine en tant que modulateurs de l'assemblage des capsides
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (fr) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Hétérocycles fonctionnalisés utiles en tant qu'agents antiviraux
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
US20230295096A1 (en) 2020-04-22 2023-09-21 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
WO2021216661A1 (fr) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. Composés de pyrazole carboxamide pour le traitement du vhb
WO2021216660A1 (fr) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. Composés d'hétéroaryle carboxamide à 5 chaînons pour le traitement du vhb
MX2022013251A (es) 2020-04-22 2022-11-14 Assembly Biosciences Inc Compuestos de heteroaril carboxamida de 5 miembros para el tratamiento de vhb.
CN113754563B (zh) * 2020-06-03 2023-09-19 浙江省化工研究院有限公司 一种2-氰基丙烯酸酯类化合物、其制备方法及应用
WO2023069547A1 (fr) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. Composés d'hétéroaryle carboxamide à 5 chaînons pour le traitement du vhb
WO2023069544A1 (fr) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. Composés d'hétéroaryl-carboxamide à 5 chaînons pour le traitement du vhb
WO2023069545A1 (fr) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. Composés d'hétéroaryle carboxamide à 5 chaînons pour le traitement du vhb
WO2023164186A1 (fr) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Composés benzothia(dia)zépine pour traitement anti-vhb et anti-vhd
WO2023164181A1 (fr) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Composés de benzothia(dia)zépine pour le traitement du vhb et du vhd
WO2023164179A1 (fr) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Composés de benzothia(dia)zépine pour le traitement du vhb et du vhd
WO2023164183A1 (fr) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Composés de benzothia(dia)zépine pour le traitement du vhb et du vhd

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50137987A (fr) * 1974-04-25 1975-11-01
DE19817262A1 (de) 1998-04-18 1999-10-21 Bayer Ag Neue 2-heterocyclisch substituierte Dihydropyrimidine
AU4289100A (en) 1999-03-25 2000-10-16 Bayer Aktiengesellschaft Dihydropyrimidines and their use in the treatment of hepatitis
DE19962010A1 (de) * 1999-12-22 2001-06-28 Bayer Ag Arzneimittelkombinationen gegen virale Erkrankungen
AU3009801A (en) 1999-12-22 2001-07-03 Bayer Aktiengesellschaft Combinations of medicaments for treating viral diseases
DE10012824A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10012823A1 (de) * 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
KR101173892B1 (ko) 2007-06-18 2012-08-16 선샤인 레이크 파르마 컴퍼니 리미티드 브로모-페닐 치환된 티아졸릴 디하이드로피리미딘
WO2010069147A1 (fr) * 2008-12-17 2010-06-24 张中能 Derives de la dihydropyrimidine, leurs compositions et leur utilisation
WO2013144129A1 (fr) * 2012-03-31 2013-10-03 F. Hoffmann-La Roche Ag Nouveaux 4-méthyl-dihydropyrimidines pour le traitement et la prophylaxie du virus de l'hépatite b

Also Published As

Publication number Publication date
EA026977B1 (ru) 2017-06-30
UY34566A (es) 2013-07-31
US20150005295A1 (en) 2015-01-01
CA2858647A1 (fr) 2013-07-11
AU2013207205A1 (en) 2014-07-03
WO2013102655A1 (fr) 2013-07-11
CN104302626B (zh) 2016-09-07
KR20150000871A (ko) 2015-01-05
EA201491329A1 (ru) 2014-10-30
ES2581489T3 (es) 2016-09-06
US9233933B2 (en) 2016-01-12
CN104302626A (zh) 2015-01-21
AR089671A1 (es) 2014-09-10
JP2015508402A (ja) 2015-03-19
KR102056665B1 (ko) 2019-12-17
CA2858647C (fr) 2020-03-31
EP2800742B1 (fr) 2016-04-06
AU2013207205B2 (en) 2017-02-02
EP2800742A1 (fr) 2014-11-12

Similar Documents

Publication Publication Date Title
JP6162144B2 (ja) ４，４−二置換−１，４−ジヒドロピリミジン、及びｂ型肝炎の処置のための医薬としてのその使用
JP7550870B2 (ja) Ｙａｐ／ｔａｚ－ｔｅａｄタンパク質－タンパク質相互作用阻害剤としてのビアリール誘導体
JP6285440B2 (ja) 融合二環式スルファモイル誘導体並びにｂ型肝炎の治療のための薬剤としてのその使用
JP6495929B2 (ja) スルファモイルピロールアミド誘導体およびｂ型肝炎の治療のための医薬としてのその使用
AU2017226004B2 (en) Inhibitors of WDR5 protein-protein binding
KR102001745B1 (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
CA2960446C (fr) Derives de n-pyridyl acetamide utilises comme inhibiteurs de la voie de signalisation wnt
JP2019532984A (ja) Ｂ型肝炎ウイルス感染症の処置及び予防のための新規なテトラヒドロピリドピリミジン
JP2015531773A (ja) スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用
JP2018527412A (ja) Ｐｅｒｋ阻害剤としての１−フェニルピロリジン−２−オン誘導体
CA2681516A1 (fr) Composes utiles en tant qu'inhibiteurs des kinases de janus
CN101918079A (zh) 蛋白激酶抑制剂及其用途
WO2016051193A1 (fr) Composés utiles en tant que modulateurs du facteur 1 de stimulation de colonies
CN104507945A (zh) 作为syk抑制剂的吡咯并[2,3-b]吡嗪
TW201341371A (zh) ４，４－二取代－１，４－二氫嘧啶類及其作為用於治療ｂ型肝炎的藥劑之用途
TW202409011A (zh) 人類呼吸道融合病毒及間質肺病毒抑制劑
TW202313609A (zh) 稠合雜環衍生物(二)
CN104024261B (zh) 咪唑并哒嗪化合物
TW202409010A (zh) 人類呼吸道融合病毒及人類間質肺炎病毒之抑制劑
CN104024261A (zh) 咪唑并哒嗪化合物

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170614

R150 Certificate of patent or registration of utility model

Ref document number: 6162144

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees